Floatz logo

Tucidinostat

Immunoproliferative Disorders

Fudan UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Immunoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Jcar017 (Lisocabtagene Maraleucel)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2B
Oricar-017
OriCell Therapeutics Co., Ltd.
Phase 1CC
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC

View all 12 →

Same molecule, other indications

Tucidinostat is also rated in:

extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →